Founder Mode: Jen Herbach, Founder & CEO, Adventris Pharmaceuticals
The Social Radars
00:00
Targeting KRAS and Which Cancers It Affects
Jen describes KRAS as a driver mutation present in ~30% of cancers, notably lung, colon, and pancreatic cancers.
Transcript
Play full episode
